Although TRAEs of special interest mostly occurred in the early phase after starting administration, 3 patients experienced TRAEs (infection or cytopenia) after 6 months of administration; therefore, careful monitoring may be required for the long-term use of BTK inhibitors. This evidence concerns the gene BTK and infection.